Regorafenib
- Generic Name
- Regorafenib
- Brand Names
- Stivarga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H15ClF4N4O3
- CAS Number
- 755037-03-7
- Unique Ingredient Identifier
- 24T2A1DOYB
- Background
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
- Indication
Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumour (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. Regorafenib is also indicated for the treatment of patients with hepatocellular carcinoma (HCC) previously treated with sorafenib.
- Associated Conditions
- Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Gastrointestinal Stromal Tumor (GIST), Locally advanced Gastrointestinal stromal tumor, Unresectable Gastrointestinal stromal tumor
- Associated Therapies
- -
Phase II Study of Regorafenib as Maintenance Therapy
- First Posted Date
- 2019-01-04
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Centre Oscar Lambret
- Target Recruit Count
- 127
- Registration Number
- NCT03793361
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷CHRU Besançon, Besançon, France
🇫🇷Centre François Baclesse, Caen, France
Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-10-19
- Last Posted Date
- 2024-08-22
- Target Recruit Count
- 52
- Registration Number
- NCT03712943
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI
- Conditions
- Interventions
- First Posted Date
- 2018-10-05
- Last Posted Date
- 2018-10-05
- Target Recruit Count
- 41
- Registration Number
- NCT03698253
- Locations
- 🇨🇳
Chung-Ho Memorial Hospital, Kaohsiung Medical University:, Kaohsiung, Taiwan
Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-09-05
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 75
- Registration Number
- NCT03657641
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Target Recruit Count
- 120
- Registration Number
- NCT03627728
- Locations
- 🇮🇹
Struttura Complessa di OncologiaIRCCS- Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
- Conditions
- Interventions
- Biological: Aldoxorubicin HydrochlorideBiological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNKDrug: AvelumabDrug: CapecitabineDrug: CetuximabDrug: CyclophosphamideDrug: 5-FluorouracilDrug: LeucovorinDrug: Nab-paclitaxelDrug: OxaliplatinDrug: RegorafenibProcedure: SBRT
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03563157
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT03555149
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
- First Posted Date
- 2018-05-11
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 22
- Registration Number
- NCT03520842
- Locations
- 🇺🇸
Stanford University School of Medicine, Palo Alto, California, United States
A Study of CS1003 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2018-03-23
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- CStone Pharmaceuticals
- Target Recruit Count
- 108
- Registration Number
- NCT03475251
- Locations
- 🇦🇺
Scientia Clinical Research Ltd, Randwick, New South Wales, Australia
(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2022-10-06
- Lead Sponsor
- Blueprint Medicines Corporation
- Target Recruit Count
- 476
- Registration Number
- NCT03465722
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Northwestern Medicine, Chicago, Illinois, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.